| Trial ID: | L4268 |
| Source ID: | NCT01965496
|
| Associated Drug: |
Pex168
|
| Title: |
A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: PEX168
|
| Outcome Measures: |
Primary: To assess HbA1C levels after 14 weeks continuous treatment, 14 weeks | Secondary: To assess Fasting blood glucose levels, 14 weeks | Other: To assess number of participants with Adverse Events as a Measure of Safety and Tolerability, 14 weeks|To assess the body weights after the treatment, 14 weeks
|
| Sponsor/Collaborators: |
Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Collaborators: People's Liberation Army General Hospital of Chengdu Military Region
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
64
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-03
|
| Completion Date: |
2013-04
|
| Results First Posted: |
|
| Last Update Posted: |
2013-10-18
|
| Locations: |
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01965496
|
